FDA extends the scope of opioid REMS to include IR and education
The FDA has approved an updated opioid analgesics risk evaluation and mitigation strategy, including measures that apply to immediate-release opioids.
Top Headlines
Global Industry News
-
Novartis ‘disappointed’ and ‘surprised’ by NICE CAR-T call
from BioPharma-Reporter.com
-
Lonza invests $418m in two biomanufacturing solutions
from BioPharma-Reporter.com
-
Phesi files patent for clinical trial protocol development method, system
from Outsourcing-Pharma.com
-
GeneOne signs licensing agreement for RNA development
from Outsourcing-Pharma.com
